Hologic, Inc. 

(Public, NASDAQ:HOLX)   Watch this stock   
Find more results for holx
Feb 1, 2010
Q1 2010 Earnings Release - 12:00PM EST - Add to calendar
Dec 1, 2009
Investment Communtiy Webcast - 9:00AM EST - Add to calendar
Dec 1, 2009
Nasdaq Conference - 6:15AM EST - Add to calendar
Nov 19, 2009
Citi Small/Mid Cap Conference
Nov 9, 2009
Q4 2009 Earnings Conference Call - Webcast
Nov 9, 2009
Q4 2009 Earnings Release
Sep 15, 2009
Morgan Stanley Global Healthcare Conference - Webcast
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2009
Net profit margin 8.67% -132.93%
Operating margin 18.80% -123.18%
EBITD margin - -120.06%
Return on average assets 2.46% -31.48%
Return on average equity 5.64% -60.83%
Employees 3,933 -

Address

35 Crosby Drive
Bedford, MA 01730
United States - Map
+1-781-9997300 (Phone)
+1-781-2800614 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Hologic, Inc. discussed on blogs

Ranking 700+ Mid-Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 4 hours ago

Hologic, Inc. discussions

  View all discussions »

Description

Hologic, Inc. (Hologic) is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. The Company manages its business in four principal segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. In July 2008, the Company acquired Third Wave Technologies, Inc. (Third Wave), a company that develops and markets molecular diagnostic reagents for a variety of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) analysis applications based on its own Invader chemistry. In October 2007, the Company completed its business combination with Cytyc Corporation, a company that develops, manufactures and markets complementary products covering a range of cancers and women’s health indications, including cervical cancer screening, prenatal diagnostics and partial breast radiation therapy.

Officers and directors

John W. Cumming
Chairman of the Board
Age: 63
Bio & Compensation - Reuters
Robert A. Cascella
President, Chief Executive Officer, Director
Age: 54
Bio & Compensation - Reuters
Glenn P. Muir
Chief Financial Officer, Executive Vice President - Finance & Administration, Treasurer, Director
Age: 49
Bio & Compensation - Reuters
Mark J. Casey
Senior Vice President, General Counsel, Assistant Secretary
Age: 45
Bio & Compensation - Reuters
John R. Pekarsky
Senior Vice President - Sales and Strategic Accounts
Age: 55
Bio & Compensation - Reuters
Peter K. Soltani
Senior Vice President - Breast Health
Age: 48
Bio & Compensation - Reuters
Howard B. Doran Jr.
Senior Vice President - Diagnostics
Age: 48
Bio & Compensation - Reuters
Stuart A. Kingsley
Senior Vice President - GYN Surgical
Age: 45
Bio & Compensation - Reuters
Jay A. Stein
Chairman Emeritus, Chief Technology Officer
Age: 66
Bio & Compensation - Reuters
David R. LaVance Jr.
Lead Independent Director
Age: 54
Bio & Compensation - Reuters